Announcements Trials

Browse Landscape

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 199 Breast Neoplasms 136 Prostatic Neoplasms 72 Neoplasms 62 Neoplasm Metastasis 52 Lung Neoplasms 45 Stomach Neoplasms 27 Parkinson Disease 4, Autosomal Dominant Lewy Body 22 Squamous Cell Carcinoma of Head and Neck 17 Ovarian Neoplasms 15 Advanced Solid Tumors 14 Recurrence 12 Head and Neck Neoplasms 11 Colorectal Neoplasms 11 Carcinoma, Squamous Cell 11 Urinary Bladder Neoplasms 10 Melanoma 10 Esophageal Neoplasms 10 HER2-positive Breast Cancer 9 Endometrial Neoplasms 9 Carcinoma, Renal Cell 9 Sarcoma 8 Esophageal Squamous Cell Carcinoma 8 Carcinoma, Transitional Cell 8 Solid Tumor 7 Prostatic Neoplasms, Castration-Resistant 7 Pancreatic Neoplasms 7 Carcinoma 7 Triple Negative Breast Neoplasms 6 Small Cell Lung Carcinoma 6

Interventions

Gemcitabine 4 Cisplatin 4 Carboplatin 3 pembrolizumab 2 erdafitinib 2 vinflunine 1 tremelimumab 1 enfortumab vedotin 1 durvalumab 1 avelumab 1 atezolizumab 1 Tiragolumab 1 Sunitinib 1 Nivolumab 1 Midazolam 1 Metformin 1 Ipilimumab 1 Docetaxel 1 4-amino-5-fluoro-3-(5-(4-methylpiperazin-1-yl)-1H-benzimidazol-2-yl)quinolin-2(1H)-one 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Urothelial Cancer × Docetaxel × Clear all

NCT03390504 2026-05-11

THOR

Janssen Research & Development, LLC

Phase 3 Active not recruiting

629 enrolled 32 charts

Urothelial Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡